In the near future, oncologists should be able to identify and manage cardiac risks, both in clinical trials and daily practice. Many successful agents – including anthracyclines and trastuzumab ...

which indicates that lapatinib exerts its main effects via the HER2 pathway. Around 1.3 million women are diagnosed with breast cancer annually worldwide, which represents 23% of all cancers in women.

The addition of trastuzumab to adjuvant chemotherapy for women with HER2-positive breast cancer is potentially associated with an increased risk of cardiac dysfunction (CD), specifically when the ...

The US Food and Drug Administration (FDA) has approved a label expansion for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, into biliary tract cancer (BTC).

According to Roche, the HER2 (4B5) clone consistently achieves high proficiency assessment scores against other clones. "FDA ...

Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test becomes the only FDA approved companion diagnostic indicated to aid assessment of HER2 low-metastatic breast cancer ...

Roche announced the US Food and Drug Administration (FDA) approval of a label expansion into biliary tract cancer (BTC) for the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test.

Roche (RHHBY) announced that the U.S. Food and Drug Administration has approved an expansion of the PATHWAY anti-HER2/neu (4B5) ...